Empowering Women in Science: Exclusive APC Discount for International Women's Day

As we embrace the vibrant spirit of spring, we also celebrate a moment of immense significance - International Women’s Day (March 8th). In honor of the remarkable achievements of women in science and to further promote gender equality in research, Cancer Drug Resistance (CDR) is proud to introduce a special, limited-time APC (Article Processing Charge) discount for female researchers.

This initiative not only recognizes the dedication of women in academia but also demonstrates our commitment to enhancing the participation of female scientists in high-impact research.

🌍 Why This Initiative?

International Women’s Day is a global celebration of women’s contributions across all fields, and CDR is committed to providing meaningful support for female researchers. By offering financial relief on APCs, we aim to encourage more women to share their groundbreaking discoveries, particularly in cancer research, drug resistance, and other critical areas.

We believe that every voice in science deserves to be heard, and every breakthrough deserves a global platform.

📅 Discount Period

• Start Date: March 8, 2025
• End Date: April 8, 2025
• Duration: 1 month

Who Is Eligible?

This initiative is open to all submissions where the first author or corresponding author is female.

💡 Two Ways to Save on APCs

1. Early Submission Discount (Full Manuscript)

Submit your full manuscript within the following time frames to enjoy an exclusive APC discount:

2. Lock in Your Discount Early (Manuscript Information Submission)

To provide more flexibility, we offer an alternative way to secure your APC discount in advance:

Simply submit your manuscript details (title, article type, abstract, and author information) by April 8, 2025, to the journal’s editorial office at 📧 editorial@cdrjournal.com, and receive a $400 APC reduction when you submit your full manuscript later.

📌 Important Notes:

• This discount remains valid until you submit your full paper, provided it is within a reasonable timeframe.
• If your final submission qualifies for a higher discount, the greater discount will be applied.
• The $400 discount cannot be combined with the percentage-based APC discounts for early full submissions.

Additional Benefits for Participating Authors

Beyond the APC reduction, CDR is offering exclusive value-added services to support female researchers:

1. Priority Peer Review

• All eligible submissions will receive accelerated peer review, with an aim to provide initial decisions within 4–6 weeks.

2. Increased Visibility & Promotion

• Published papers will be featured on the journal’s website, email newsletters, and social media platforms (X/Twitter, LinkedIn, WeChat, etc.) for broader exposure.
• Selected high-impact articles will receive special highlights in journal newsletters, boosting research visibility.

3. Exclusive Author Interviews & Webinars

• Selected female authors will be invited for online academic interviews or panel discussions, sharing their research journeys and groundbreaking discoveries.

• Featured researchers may also present at CDR-hosted online symposia, further increasing their academic influence.

What Types of Articles Qualify?

All submission types are eligible, including:

• Original Research
• Review Articles
• Commentaries
• Perspectives
• Opinions

🔹 Note: The APC discount will be applied only after the manuscript has successfully passed peer review and is accepted for publication.

We warmly invite female researchers worldwide to take advantage of this special initiative and contribute to advancing gender equality in academia. Your research is not just a scientific achievement—it is a testament to resilience, dedication, and innovation.

Women scientists are at the forefront of revolutionizing personalized cancer treatment, tackling the most pressing challenges with brilliance and determination. Their work is not only deepening our understanding of cancer but also offering new hope to patients worldwide.

On this special occasion, let’s celebrate the extraordinary contributions of female scientists and recognize their invaluable role in pushing the boundaries of cancer research. May their insights and discoveries continue to illuminate the path toward a future free from cancer!

Submit your research and be part of this transformative movement!

For any inquiries, please contact the editorial office at editorial@cdrjournal.com.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance